Sclerosol Intrapleural Aerosol

Company
Bryan Corporation

Approval Status
Approved January 1998

Treatment for
malignant pleural effusions

Areas
Cancer & Oncology , Respiratory

Sclerosol Intrapleural Aerosol has been approved for the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy.

Sclerosol_intrapleural_aerosol Drug Information

The Sclerosol_intrapleural_aerosol drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top